Literature DB >> 12955176

Human leukocyte antigen-DR expression in peripheral blood mononuclear cells from healthy donors influenced by the sera of injured patients prone to severe sepsis.

Anke Mueller1, Ernst Kreuzfelder1, Baerbel Nyadu1, Monika Lindemann1, Vera Rebmannn1, Matthias Majetschak2, Udo Obertacke2, Ulrich F Schade3, Dieter Nast-Kolb3, Hans Grosse-Wilde4.   

Abstract

OBJECTIVE: To study the influence of sera from severely injured patients on the human leukocyte antigen (HLA)-DR expression of normal peripheral blood mononuclear cells (PBMC).
DESIGN: In vitro study.
SETTING: University hospital. PATIENTS AND PARTICIPANTS: Sera from 34 patients were obtained within 8 h after trauma. Seventeen of these patients developed posttraumatic sepsis (sepsis group) and 17 recovered without infectious complications. Sera from ten healthy individuals served as controls. Phytohemagglutinin (PHA)-activated PBMC from 44 healthy donors were used to study the effects of a patient's serum. MEASUREMENTS AND
RESULTS: Medium containing 5% of serum from the sepsis group significantly ( p<0.05) reduced the HLA-DR expression (channels, mean +/- standard error of the mean) on monocytes (patients 883+/-22, controls 962+/-15), B (patients 922+/-14, controls 972+/-7) and T cells (patients 932+/-13, controls 968+/-5) of PHA-activated PBMC. Significantly increased accumulation of TNFalpha on (1.8+/-0.4% of PBMC) and within T cells (0.98+/-0.26% of PBMC) was observed by flow cytometry after incubation with medium containing sera of the sepsis group compared with controls (on 0.5+/-0.1%, within 0.27+/-0.05% of PBMC). A significant negative correlation between relative cell counts of intracellular TNFalpha-positive T cells with HLA-DR expression was observed for monocytes ( r= -0.61), B cells ( r= -0.57) and proliferation ( r= -0.68) as estimated by (3)H-thymidine uptake [patients 139971+/-12844 counts per minute (cpm), controls 198973+/-19347 cpm, p<0.05] in the presence of sera from the sepsis group.
CONCLUSIONS: Reduced cellular immunity and, therefore, immunodeficiency after trauma appears to be caused by soluble factors influencing T cell function in particular.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955176     DOI: 10.1007/s00134-003-1992-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  1 in total

1.  Regulation of MHC class II antigen expression. Opposing effects of tumor necrosis factor-alpha on IFN-gamma-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell.

Authors:  Y Watanabe; C O Jacob
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

  1 in total
  4 in total

Review 1.  Year in review in intensive care medicine: 2003. II. Brain injury, hemodynamics, gastrointestinal tract, renal failure, metabolism, trauma, and postoperative.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-15       Impact factor: 17.440

2.  Endothelial oxidative stress induced by serum from patients with severe trauma hemorrhage.

Authors:  Christian Laplace; Olivier Huet; Eric Vicaut; Catherine Ract; Laurent Martin; Dan Benhamou; Jacques Duranteau
Journal:  Intensive Care Med       Date:  2005-07-28       Impact factor: 17.440

3.  Expression and function of Toll-like receptor 9 in severely injured patients prone to sepsis.

Authors:  E E Baiyee; S Flohe; S Lendemans; S Bauer; N Mueller; E Kreuzfelder; H Grosse-Wilde
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

4.  Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines.

Authors:  Thierry Fumeaux; Julien Dufour; Sabine Stern; Jérôme Pugin
Journal:  Intensive Care Med       Date:  2004-09-11       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.